Evidence map›Paper›PMID 28705808›Full record

ArticleMolecular pharmacology2017

Molecular Basis of Altered hERG1 Channel Gating Induced by Ginsenoside Rg3.

Alison Gardner, Wei Wu, Steven Thomson, Eva-Maria Zangerl-Plessl, Anna Stary-Weinzinger, Michael C Sanguinetti

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Pharmacological activation of the hERG KJournal of arrhythmia · 2022
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Alison GardnerNora Eccles Harrison Cardiovascular Research and Training Institute (A.G., W.W., S.T., M.C.S.) and Division of Cardiovascular Medicine, Department of Internal Medicine, (M.C.S.), University of Utah, Salt Lake City, Utah; and Department of Pharmacology and Toxicology, University of Vienna, Vienna, Austria (E.-M.Z.-P., A.S.-W.).
Wei WuNora Eccles Harrison Cardiovascular Research and Training Institute (A.G., W.W., S.T., M.C.S.) and Division of Cardiovascular Medicine, Department of Internal Medicine, (M.C.S.), University of Utah, Salt Lake City, Utah; and Department of Pharmacology and Toxicology, University of Vienna, Vienna, Austria (E.-M.Z.-P., A.S.-W.).
Steven ThomsonNora Eccles Harrison Cardiovascular Research and Training Institute (A.G., W.W., S.T., M.C.S.) and Division of Cardiovascular Medicine, Department of Internal Medicine, (M.C.S.), University of Utah, Salt Lake City, Utah; and Department of Pharmacology and Toxicology, University of Vienna, Vienna, Austria (E.-M.Z.-P., A.S.-W.).
Eva-Maria Zangerl-PlesslNora Eccles Harrison Cardiovascular Research and Training Institute (A.G., W.W., S.T., M.C.S.) and Division of Cardiovascular Medicine, Department of Internal Medicine, (M.C.S.), University of Utah, Salt Lake City, Utah; and Department of Pharmacology and Toxicology, University of Vienna, Vienna, Austria (E.-M.Z.-P., A.S.-W.).
Anna Stary-WeinzingerNora Eccles Harrison Cardiovascular Research and Training Institute (A.G., W.W., S.T., M.C.S.) and Division of Cardiovascular Medicine, Department of Internal Medicine, (M.C.S.), University of Utah, Salt Lake City, Utah; and Department of Pharmacology and Toxicology, University of Vienna, Vienna, Austria (E.-M.Z.-P., A.S.-W.).
Michael C SanguinettiNora Eccles Harrison Cardiovascular Research and Training Institute (A.G., W.W., S.T., M.C.S.) and Division of Cardiovascular Medicine, Department of Internal Medicine, (M.C.S.), University of Utah, Salt Lake City, Utah; and Department of Pharmacology and Toxicology, University of Vienna, Vienna, Austria (E.-M.Z.-P., A.S.-W.) m.sanguinetti@utah.edu.
University of Vienna · ATUniversity of Utah · US

Funding

Molecular mechanisms of hERG1 channel activatorsR01HL055236 · NHLBI · UNIVERSITY OF UTAH · PI SANGUINETTI, MICHAEL CRAIG · 1996 to 2015
$5.3M
Austrian Science Fund FWF W 1232NHLBI NIH HHS R01 HL055236
6 · The paper itself

Abstract

Outward current conducted by human

Indexed as

AnimalsDose-Response Relationship, DrugEther-A-Go-Go Potassium ChannelsGinsenosidesHumansIon Channel GatingProtein Structure, SecondaryXenopus laevisEther-A-Go-Go Potassium Channelsginsenoside Rg3GinsenosidesKCNH1 protein, human

Identifiers

PMID28705808
PMCPMC5588553
OpenAlexW2734975392

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.